The FDA has granted marketing authorization to CT-132, an adjunctive, prescription digital therapeutic for the preventive treatment of episodic migraine.

The software-based intervention aims to reduce brain hypersensitivity in patients with migraine by modulating responses to environmental and internal stimuli through a 12-week program.

Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. The company's Gloperba, licensed from Romeg Therapeutics, is a ...

Psychedelics drugs with the hallucinatory effects shut down show promise in reconnecting broken neural synaptic connections, which are the cause of some grave diseases.

This is part of a growing industry trend towards the use of digital therapeutics. Hyfe’s technology, developed in partnership with KYORIN Pharmaceutical Co., makes it possible for patients to monitor ...

This need could be met by prescription digital therapeutics, which are not associated with adverse events (AEs) or other polypharmacy concerns, they added. Screenshot from the CT-132 prescription ...

Keep in mind, there’s a big difference between holistic wellness apps and actual digital therapeutics that connect you to a licensed mental health provider. Apps can only go so far. There may be ...

7 analysts have shared their evaluations of Voyager Therapeutics VYGR during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise ...

Lupin Digital Health marked the company’s foray into the fast-growing digital therapeutics space. Its Lyfe platform focuses on real-time monitoring of patients and offers interventions for ...

The GCC Countries Digital Health Market is expected to witness a healthy and a double-digit growth by 2027. The key factors driving the growth of the GCC Countries Digital Health Market are favorable ...